Guardant Health Stock
Bio-tech company focus on oncology
Sign up today and learn more about Guardant Health Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Guardant Health Stock
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Investors
8VC
Anduril Industries, Sila Nanotechnologies, Cityblock Health, project44, Blend, Aspiration, Addepar, Illumio, BlueVoyant, Guardant Health
Felicis Ventures
Wish, Scopely, Opendoor, Dollar Shave Club, Gusto, Zipline, Coalition, Plaid, Crusoe Energy Systems, Guild Education
Formation 8
Wish, Oscar Health, Virgin Hyperloop One, Collective Health, Blend, Illumio, Guardant Health, Bolt Threads, Aviatrix, Gradiant
Khosla Ventures
Instacart, Stripe, DoorDash, Impossible Foods, Palantir Technologies, Commonwealth Fusion, View, Zenefits, Eat Just, Opendoor
Lightspeed Venture Partners
Snap, OYO, AppDynamics, TripActions, Faire, Affirm, Netskope, LivingSocial, Weee!, ThoughtSpot
Sequoia Capital
Market Kurly, Robinhood, Airbnb, Instacart, Tokopedia, Stripe, DoorDash, Rappi, CoinSwitch Kuber, UiPath
SoftBank Capital
Alibaba, SoFi, Ola, Compass, Snapdeal, Plenty, Guardant Health, BuzzFeed, Fitbit, Lemonade
Temasek Holdings
PharmEasy, Tokopedia, Ola, Magic Leap, DoorDash, Impossible Foods, Commonwealth Fusion, Wish, Snyk, AvidXchange
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Funding History
| April 2013 | $9.2M |
|---|---|
| April 2014 | $32.6M |
| December 2014 | $56.0M |
| December 2015 | $83.9M |
| May 2017 | $334M |
Management
Chief Executive Officer
Helmy Eltoukhy
Chief Financial Officer
Derek Bertocci
Chief Legal Officer
Michael Wiley
Chief Medical Officer
Richard Lanman
COO & President
AmirAli Talasaz
VP of Marketing
Sandra Finley
Head of Sales
Stanley Welle
VP of Bioinformatics
Darya Chudova
Vice President, Pharma Business Development
Daniel Simon
Press
Fairfield Current - Nov, 6 2018
Guardant Health (NASDAQ:GH) Coverage Initiated by Analysts at Bank of AmericaNasdaq - Nov, 1 2018
October's winners & losers: Growth IPOs still fly highNasdaq Place (press release) - Oct, 31 2018
Guardant Health, Inc. (GH) moves -0.38% below SMA-50TechCrunch - Oct, 28 2018
These 14 startups — endorsed by the seed-stage investment firm Pear — just hit the fundraising trailMarketWatch - Sep, 6 2018
Cancer blood-testing company Guardant Health files for IPOGenomeWeb - Jul, 31 2018
Guardant Silent on TMB Plans as Study Adds Evidence for Immunotherapy Prediction in BloodForbes - Jul, 19 2018
Liquid Biopsy Controversy Rages On- Jul, 12 2018
Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer ApplicationsPR Newswire (press release) - May, 23 2018
Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications ...PR Newswire (press release) - Apr, 26 2018
Guardant Health Publishes Extensive Validation of Guardant360® Assay Comprising Largest-Published Blood-Tissue ...Healthcare Trends - Apr, 7 2018
Guardant Health Inc Market Analysis 2018 to 2025PR Newswire (press release) - Mar, 19 2018
Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer PatientsPR Newswire (press release) - Mar, 13 2018
Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer TrialPR Newswire (press release) - Feb, 15 2018
The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDAMedgadget (blog) - Feb, 12 2018
Liquid Biopsy Market Growing Rates of Cancer Coupled with ...Incredible News 24 - Jan, 22 2018
Global Liquid Biopsy Market Projections 2018- Guardant Health, RainDanceTechnologies and BiocartisPR Newswire (press release) - Nov, 16 2017
Guardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with ...PR Newswire (press release) - Nov, 6 2017
Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung CancerMedgadget (blog) - Oct, 17 2017
Liquid Biopsy Market Size Is Anticipated To Reach $5.96 Billion By ...Healio - Oct, 5 2017
Liquid biopsies predict response to immunotherapyPR Newswire (press release) - Sep, 26 2017
Guardant Health Receives Investigational Device Exemption Approval from the FDA to Support Merck KGaA ...Financial Times - Sep, 24 2017
DNA start-ups attract cash from venture fundsGenomeWeb - Jun, 22 2017
Guardant Health Sues Foundation Medicine for False AdvertisingGenomeWeb - Jun, 5 2017
Guardant Health, Foundation Medicine to Participate in Cure-One N1 RegistryPR Newswire (press release) - Jun, 3 2017
Cure-One™ Announces Partnership with Guardant HealthGenomeWeb - May, 24 2017
New York Approves Guardant Health's Liquid Biopsy TestPR Newswire (press release) - May, 18 2017
Guardant Health Announces Draft Medicare Local Coverage Determination for the Guardant360 AssayNews-Medical.net - May, 15 2017
Guardant Health introduces new initiative to sequence tumor DNA of one million cancer patientsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
